NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights

Rhea-AI Summary

NetraMark (OTCQB: AINMF) announced four new contracts with a leading global pharmaceutical company, signed under an existing master services agreement, to apply its proprietary NetraAI platform to clinical data from four late-stage pivotal studies on November 18, 2025.

The engagements will perform multi-study analyses to identify explainable patient subpopulations driving treatment and placebo response and to quantify clinical and demographic drivers of trial variability. NetraAI is described as a mathematically-augmented, interpretable AI system intended to align with FDA expectations for explainable AI in clinical development.

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics supporting multiple late-stage clinical studies.

Under the terms of the agreements, NetraMark’s proprietary NetraAI platform will be applied to clinical data from four pivotal studies to help uncover and characterize patient subpopulations that drive treatment response, placebo response, and overall trial variability. The work aims to enhance understanding of complex patient populations.

“The signing of these four contracts represents a significant expansion of our ongoing collaboration with a leading pharmaceutical company,” said George Achilleos, Chief Executive Officer of NetraMark. “Our NetraAI system seeks to generate explainable insights from complex, heterogeneous clinical datasets — enabling sponsors to better understand their patient populations and make more informed development decisions.”

Across the engagements, NetraMark will conduct multi-study analyses which seek to:

• Identify explainable subpopulations that characterize treatment and placebo response patterns;

• Quantify clinical and demographic variables that influence variability in study outcomes.
  
  

Each of the four studies will leverage NetraAI, a mathematically-augmented AI system capable of identifying high-effect-size subgroups within complex datasets without relying on opaque “black box” modeling. This interpretability is essential for aligning with the U.S. Food and Drug Administration’s (FDA) evolving expectations for explainable AI methods in clinical development.

The contracts were executed under an existing master services agreement reflecting ongoing engagement from the sponsor and continued confidence in NetraMark’s technology, and also represent new discrete projects.

About NetraAI
In contrast to other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) providing the potential to increase the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.

About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the Company’s technology’s ability to uncover and characterize patient subpopulations and treatment and placebo response patterns, generate explainable insights to better understand patient populations and make informed development decisions, drive treatment response, placebo response, and overall trial variability and understand complex patient populations, and quantify clinical and demographic variables that influence variability in study outcomes, NetraAI’s ability to align with FDA”s expectations for AI methods in clinical development and NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu – CFO | swapan@netramark.com | 403-681-2549

FAQ

What did NetraMark (AINMF) announce on November 18, 2025?

NetraMark announced four contracts with a leading global pharmaceutical company to apply NetraAI to four late-stage pivotal clinical studies.

How will NetraMark’s NetraAI be used in the AINMF engagements?

NetraAI will perform multi-study analyses to identify explainable subpopulations and quantify clinical and demographic variables that influence study variability.

Are the November 18, 2025 AINMF contracts part of an existing agreement?

Yes, the contracts were executed under an existing master services agreement and represent new discrete projects under that engagement.

What stage of trials will NetraAI support for AINMF’s partner?

The work will support multiple late-stage pivotal clinical studies.

Does NetraMark say NetraAI meets FDA expectations for explainable AI for clinical development?

The company states NetraAI is interpretable and aligns with the FDA’s evolving expectations for explainable AI methods in clinical development.

What specific insights will the AINMF contracts aim to deliver to the sponsor?

The engagements aim to uncover and characterize patient subpopulations driving treatment response, placebo response, and overall trial variability.